<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818323</url>
  </required_header>
  <id_info>
    <org_study_id>2012-001654-25</org_study_id>
    <nct_id>NCT01818323</nct_id>
  </id_info>
  <brief_title>Phase I Trial: T4 Immunotherapy of Head and Neck Cancer</brief_title>
  <official_title>Phase I Trial: T4 Immunotherapy of Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to investigate the safety of T4 immunotherapy when&#xD;
      administered to treat loco-regional disease in Squamous Cell Cancer of the Head and Neck&#xD;
      (SCCHN) that is not suitable for conventional active therapy.&#xD;
&#xD;
      The investigators propose to conduct an open-labelled, non-randomized, dose-escalation phase&#xD;
      I trial in which autologous T4+ T-cells are administered to patients with SCCHN. T-cells will&#xD;
      be engineered to express a second generation chimeric antigen receptor (CAR) named T1E28z.&#xD;
      Engineered T-cells will be injected directly into the tumour site. Patients will not be&#xD;
      lymphodepleted. A classical 3+3 design will be employed, with dose escalation from 10^7&#xD;
      through to 10^9 transduced T4+ T-cells, dependent upon toxicity monitoring. It is anticipated&#xD;
      that up to 30 patients will be enrolled over the course of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further information is provided in van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T,&#xD;
      Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of&#xD;
      ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and&#xD;
      neck cancer. Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. doi: 10.1089/humc.2013.144.&#xD;
      PubMed ID: 24099518&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1/Phase 2 studies typically have at least one Intervention Type of Drug, Biological/Vaccine or Combination Product.&#xD;
In this dose escalation study, the intervention consists of intratumoral delivery of panErbB-specific CAR T cells, administered alone or following lymphodepleting chemotherapy with fludarabine and cyclophosphamide.&#xD;
This note has been added in response to the warning &quot; WARNING: Phase 1/Phase 2 studies typically have at least one Intervention Type of Drug, Biological/Vaccine or Combination Product.&quot;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities for T4 immunotherapy in SCCHN and determine a safe and feasible recommended dose for phase II testing of intra-tumoral T4 immunotherapy.</measure>
    <time_frame>Up to 6 weeks post T4 administration</time_frame>
    <description>Patients will be monitored intensely for the first 24 hours post T4 administration. Patients will the be assessed for signs of toxicity on days 3-4, 5-7, 8, 15, 29 and 43.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate serum cytokine levels after administration of T4 immunotherapy</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate persistence of T4+ T-cells at the site of administration and in the peripheral circulation</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To achieve preliminary assessment of anti-tumour activity, using cross-sectional imaging to quantify objective responses</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate tumour ErbB receptor phenotype, before and after administration of T4 immunotherapy</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate immunomodulatory effects of metronomic cyclophosphamide on T4 immunotherapy</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
    <description>Pre- and post-treatment absolute number of circulating T-regulatory cells will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate effect of T4 immunotherapy upon immune reactivity against endogenous tumour antigens</measure>
    <time_frame>up to 6 weeks post T4 administration</time_frame>
    <description>ELISPOT will be performed on blood samples taken 3 days prior and 29 days after T4 administration to measure for MAGE-reactive T-cells.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Intra-tumoral T4 immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intra-tumoral T4 immunotherapy</intervention_name>
    <description>Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide</description>
    <arm_group_label>Intra-tumoral T4 immunotherapy</arm_group_label>
    <other_name>4ab T1E28z positive T-cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically and/ or cytologically confirmed SCCHN.&#xD;
&#xD;
          2. 18 years or older.&#xD;
&#xD;
          3. Locally advanced and/ or recurrent head and neck cancer with or without metastatic&#xD;
             disease (excluding brain metastases) for whom no standard therapy remains or is&#xD;
             suitable.&#xD;
&#xD;
          4. Regarding previous treatment, patients may have received prior systemic therapy,&#xD;
             including platinum chemotherapy, at least one month earlier. In the presence of&#xD;
             metastatic disease, recent short-course palliative radiotherapy to non-target site(s)&#xD;
             is allowed.&#xD;
&#xD;
          5. Those who refuse palliative treatment may be eligible for participation. However,&#xD;
             their reasons for not opting for palliative treatment must be explored thoroughly.&#xD;
&#xD;
          6. At least one loco-regional target lesion measurable by RECIST v1.1 criteria on CT or&#xD;
             MRI scanning within four weeks of enrolment, and amenable to intra-tumoral injection.&#xD;
&#xD;
          7. Eastern Co-operative Oncology Performance Status of 0-2.&#xD;
&#xD;
          8. Normal cardiac function as assessed by electrocardiography and either echocardiography&#xD;
             (ECHO), or multi-gated acquisition (MUGA) scanning. Left ventricular ejection fraction&#xD;
             must be &gt; 50%. Assessment must take place within four weeks of enrolment.&#xD;
&#xD;
          9. Haematology results within seven days of enrolment: neutrophils &gt;1.5 x 109/L,&#xD;
             platelets &gt;100 x 109/L, haemoglobin &gt;9g/dl, INR &lt;1.5.&#xD;
&#xD;
         10. Biochemistry results within seven days of enrolment: • serum creatinine &lt;1.5 upper&#xD;
             limit of normal • bilirubin &lt;1.25 times normal; • ALT/ AST &lt;2.5 times upper limit of&#xD;
             normal (&lt;5 times upper limit of normal if liver metastases present)&#xD;
&#xD;
         11. Female patients must be postmenopausal (12 months of amenorrhea), surgically sterile&#xD;
             or they must agree to use a physical method of contraception. Oral or injectable&#xD;
             contraceptive agents cannot be the sole method of contraception. Women of childbearing&#xD;
             potential (WOCB) who receive cyclophosphamide must adhere to these contraceptive&#xD;
             requirements during the trial and until 3 months after the last dose of&#xD;
             cyclophosphamide. Male patients, even if sterilized, must agree to use a barrier&#xD;
             method of contraception. Male subjects must also commit to use a barrier method of&#xD;
             contraception until at least 3 months after the end of study treatment.&#xD;
&#xD;
         12. Written informed consent prior to registration.&#xD;
&#xD;
         13. Eligible for NHS care in the UK.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of or imminent occurrence of airway obstruction, unless tracheostomy in&#xD;
             place.&#xD;
&#xD;
          2. The presence of or imminent occurrence of tumour-mediated infiltration of major blood&#xD;
             vessels.&#xD;
&#xD;
          3. Positive history of HIV-1, HIV-2, HTLV-1, HTLV-2, Hepatitis B, Hepatitis C or syphilis&#xD;
             infection.&#xD;
&#xD;
          4. Prior splenectomy.&#xD;
&#xD;
          5. Clinically active autoimmune disease. Sub-clinical or quiescent autoimmune disease&#xD;
             does not exclude from participation.&#xD;
&#xD;
          6. Treatment in the preceding week with systemic corticosteroids (&gt; 20mg prednisolone/&#xD;
             day), any systemic immunomodulatory agent, radiotherapy, chemotherapy or&#xD;
             investigational medicinal product.&#xD;
&#xD;
          7. Concurrent use of anticoagulant therapy is not permissible.&#xD;
&#xD;
          8. The presence of major co-morbidity likely to impair ability to undergo trial therapy,&#xD;
             such as recent myocardial infarction, congestive cardiac failure or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          9. The presence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
         10. Cyclophosphamide allergy (Cohort 6 only).&#xD;
&#xD;
         11. Pregnancy.&#xD;
&#xD;
         12. Breastfeeding.&#xD;
&#xD;
         13. Prior T4 immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Maher, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Maher, MD PhD</last_name>
    <phone>(+44) 02071881468</phone>
    <phone_ext>81468</phone_ext>
    <email>john.maher@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Facility, Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Maher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, Burbridge SE, Kao V, Liu Z, Bosshard-Carter L, Van Schalkwyk MC, Box C, Eccles SA, Mather SJ, Wilkie S, Maher J. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012 May 9;18:565-76. doi: 10.2119/molmed.2011.00493.</citation>
    <PMID>22354215</PMID>
  </reference>
  <reference>
    <citation>Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der Stegen SJ, Spicer JF, Davies DM, Maher J. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010 Aug 13;285(33):25538-44. doi: 10.1074/jbc.M110.127951. Epub 2010 Jun 18.</citation>
    <PMID>20562098</PMID>
  </reference>
  <reference>
    <citation>van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. doi: 10.1089/humc.2013.144.</citation>
    <PMID>24099518</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>John Maher</investigator_full_name>
    <investigator_title>Consultant and Senior Lecturer in Immunology</investigator_title>
  </responsible_party>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Phase I trial</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

